🇺🇸 US Stock Screener ← Switch market ⚡ HerAI

IRIDEX Corporation IRIX PHARMA

Healthcare · Medical Devices · United States
https://www.iridex.com
Company Profile ↓
$0.68
-42.17% 1Y
Mkt Cap$11.94M
P/E-3.40
P/B-4.96
52W High$1.56
52W Low$0.68
Book Value$-0.14
EPS (TTM)$-0.20

Company Overview

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. In addition, it offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform transscleral laser therapy; G-Probe and G-Probe Illuminate, which are used in procedures to treat uncontrolled and refractory glaucoma; and EndoProbe family of products that are used for endophotocoagulation. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics through direct and independent sales force in the United States, as well as through independent distributors internationally. It operates in the United States, Europe, the Middle East, Africa, the Asia/Pacific region, and the Americas. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.

Why Investors Should Care

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Jan 2026 Revenue of $52.67M (+8.2% YoY); net profit $-4.44M.
  • Trailing 12 Months Year-on-year growth — revenue -7.4%.
  • 5-Year Trend Long-term compounding — revenue CAGR 3.4%.

Growth & Price Performance

Compounded Sales Growth

5 Years:3.36%
1 Year:-7.40%

Stock Price Performance

1 Year:-42.17%
6 Months:-46.69%
3 Months:-38.52%
1 Month:-17.78%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish
52-Week Range 0% of range
$0.68 $1.56
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMABelow
  • RSI (14)28.79 · Oversold
Price Performance
1M-17.78%
3M-38.52%
6M-46.69%
1Y-42.17%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Generates positive free cash flow.

CONS

  • Trading 56.3% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-3.40
Industry PE
24.83
Forward P/E
-
PEG Ratio
0.94
Book Value
$-0.14
Price to Book
-4.96
P/S
0.23
EV/EBITDA
-6.44
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
3.36%
Profit 5Y
-
Revenue (YoY)
-7.40%
Earnings (YoY)
-

Profitability & Returns

ROCE
-16.13%
ROE
-73.15%
ROA
-5.90%
Profit Margin
-6.88%
Op Margin
-8.19%
Gross Margin
35.92%
EPS (Latest Qtr)
$-0.03
EPS (TTM)
$-0.20

Balance Sheet & Liquidity

Debt/Equity
1.10
Quick Ratio
0.89
Current Ratio
1.82
Debt
$4.01M
Total Assets
$28.27M
Current Assets
-
Working Capital
-

Ownership

Promoter Holding
36.82%
Chg in Prom Hold
0.09%
FII / Inst Holding
19.46%
Chg in FII Hold
1.44%

Financial Snapshot

Enterprise Value
$11.94M
Total Revenue (TTM)
$51.57M
EBITDA
$-2.60M
Free Cash Flow
$1.64M
Operating Cash Flow
$-1.73M
Shares Outstanding
17.56M
Gross Margin
35.92%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 IRIX IRIDEX Corporation PHARMA 0.68 -3.40 $11.94M 0.00% -16.13% -73.15% 3.36% -
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,123.91 37.80 $1.00T 0.60% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 269.12 31.22 $648.55B 1.98% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 248.78 70.48 $439.62B 2.78% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 148.46 118.77 $366.28B 2.31% - 6.96% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 400.84 25.74 $359.79B 2.47% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 137.70 20.80 $261.73B 3.36% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 160.04 23.99 $248.20B 2.00% 15.97% 21.96% 9.82% 45.96%
9 TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA 603.02 32.49 $222.97B 0.29% 8.14% 13.51% 8.81% 12.95%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Sep 2013Mar 2014Jun 2014Sep 2014Apr 2015Jul 2015Oct 2015Apr 2016Jul 2016Oct 2016Dec 2016Apr 2017Jul 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Mar 2019Jun 2019Sep 2019Mar 2020Jun 2020Sep 2020Apr 2021Jul 2021Oct 2021Apr 2022Jul 2022Oct 2022Apr 2023Jul 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Apr 2026
Revenue -------------10.87M-9.51M10.30M11.32M10.60M10.43M10.66M9.02M6.22M8.80M11.96M13.43M13.26M13.39M13.76M14.63M13.71M12.86M12.85M11.76M12.63M11.58M11.90M13.57M12.48M11.80M
Gross Profit 4.72M5.05M5.30M5.15M5.41M4.22M4.84M5.30M5.73M4.25M5.56M4.46M4.50M4.37M2.17M3.92M4.27M4.58M4.26M4.55M4.28M3.92M2.41M3.65M4.94M6.11M5.78M5.98M6.27M6.46M5.94M5.36M5.62M4.46M5.13M4.32M5.05M4.68M4.01M4.74M
Operating Income 665.00K597.00K400.00K606.00K403.00K-747.00K143.00K152.00K-394.00K-1.25M-1.08M-1.86M-2.74M-3.07M-5.22M-3.62M-3.28M-3.06M-3.04M-2.47M-1.85M-1.65M-2.78M-1.85M-1.84M-1.14M-2.16M-2.28M-2.16M-1.70M-2.34M-2.89M-1.69M-3.29M-2.64M-1.87M-205.00K-940.00K-1.41M-324.00K
Net Income 530.00K487.00K297.00K490.00K246.00K-652.00K442.00K101.00K-328.00K-671.00K-10.81M-1.87M-2.75M-3.10M-5.16M-3.60M-3.28M-3.07M-3.05M-2.42M-1.78M-1.65M-2.78M-1.72M-2.01M1.39M-2.17M-2.39M-2.24M-1.77M-2.09M-2.77M-1.75M-3.46M-2.68M-1.93M-1.69M-994.00K-1.57M-524.00K
Diluted EPS 0.050.050.030.050.02-0.070.040.01-0.03-0.07-1.04-0.16-0.24-0.27-0.44-0.31-0.28-0.26-0.22-0.18-0.13-0.12-0.20-0.12-0.140.09-0.14-0.15-0.14-0.11-0.13-0.17-0.11-0.21-0.16-0.12-0.10-0.06-0.09-0.03
R&D Expense 923.00K1.19M1.31M1.10M1.28M1.48M1.24M1.36M1.39M1.26M1.36M1.34M1.37M1.32M1.28M1.10M901.00K1.15M958.00K929.00K1.01M719.00K807.00K869.00K1.17M1.67M1.79M2.12M1.92M1.69M1.75M1.84M1.54M1.54M1.50M1.30M876.00K871.00K972.00K905.00K

Profit & Loss (Annual)

Figures in USD.

Metric Jan 2010Jan 2011Dec 2011Dec 2012Dec 2013Jan 2015Jan 2016Dec 2016Dec 2017Dec 2018Dec 2019Jan 2021Jan 2022Dec 2022Dec 2023Dec 2024Jan 2026
Revenue 31.03M32.31M33.16M33.86M38.27M42.81M41.76M46.16M41.59M42.60M43.45M36.35M53.90M56.97M51.87M48.67M52.67M
Gross Profit 15.44M16.20M16.29M16.35M18.59M21.41M19.95M20.84M15.50M17.47M17.94M15.56M22.83M25.37M21.81M19.50M19.23M
Operating Income 1.23M1.19M1.93M-860.00K2.63M2.59M288.00K-2.56M-12.89M-12.87M-8.97M-6.58M-7.53M-7.54M-10.01M-8.30M-2.57M
Net Income 2.58M3.05M2.61M1.44M2.23M10.04M474.00K-11.71M-12.87M-12.81M-8.81M-6.33M-5.22M-7.55M-9.57M-8.91M-4.44M
Diluted EPS -0.300.260.160.220.970.05-1.15-1.11-1.05-0.64-0.46-0.34-0.47-0.59-0.54-0.26
R&D Expense 3.31M3.75M3.91M4.38M3.68M4.63M5.21M5.37M5.21M4.01M3.68M3.28M6.87M7.17M6.83M5.45M3.67M

Balance Sheet (Annual)

Figures in USD.

Metric Jan 2009Jan 2010Jan 2011Dec 2011Dec 2012Dec 2013Jan 2015Jan 2016Dec 2016Dec 2017Dec 2018Dec 2019Jan 2021Jan 2022Dec 2022Dec 2023Dec 2024Jan 2026
Total Assets --29.22M32.15M28.91M33.68M41.82M41.82M48.14M41.65M41.67M34.81M27.97M48.69M42.29M34.44M29.14M29.15M
Total Equity 11.75M15.03M19.43M22.43M21.91M25.85M33.74M33.69M39.16M30.52M29.96M22.70M17.37M23.30M17.23M9.52M2.10M4.92M
Cash & Equivalents 4.48M8.37M8.35M10.79M11.90M13.44M13.30M9.99M23.75M21.71M21.19M12.65M11.63M23.85M13.92M7.03M2.39M6.03M
Long Term Debt ------------1.25M---1.00M-
Total Liabilities --9.79M9.72M7.01M7.82M8.08M8.13M8.98M11.12M11.71M12.11M10.60M25.39M25.06M24.91M27.04M24.23M
Current Liabilities --9.20M8.91M6.37M7.36M7.04M7.43M8.17M10.39M10.50M9.78M8.68M12.65M12.45M12.97M16.56M13.21M

Cash Flows (Annual)

Figures in USD.

Metric Jan 2010Jan 2011Dec 2011Dec 2012Dec 2013Jan 2015Jan 2016Dec 2016Dec 2017Dec 2018Dec 2019Jan 2021Jan 2022Dec 2022Dec 2023Dec 2024Jan 2026
Operating Cash Flow 3.01M1.14M2.25M-1.14M767.00K4.01M-593.00K--3.56M-10.03M-7.91M-3.24M8.22M-9.52M-6.75M-7.29M-2.12M
Investing Cash Flow -190.00K-418.00K-278.00K-722.00K-763.00K-1.03M-1.30M--782.00K-827.00K-509.00K-93.00K-5.56M-286.00K-109.00K-13.00K-143.00K
Financing Cash Flow -1.66M-2.27M-327.00K-2.39M1.03M-3.13M-1.42M-2.31M10.38M-156.00K2.47M9.47M-73.00K-5.00K2.60M5.96M
Capital Expenditure -190.00K-193.00K-203.00K-394.00K-380.00K-568.00K-875.00K-1.06M-575.00K-440.00K-128.00K-97.00K-213.00K-286.00K-109.00K-13.00K-143.00K
Free Cash Flow 2.82M943.00K2.05M-1.53M387.00K3.45M-1.47M--4.14M-10.46M-8.04M-3.33M8.00M-9.80M-6.85M-7.30M-2.26M
Share Buybacks 00648.00K2.83M426.00K4.67M1.56M59.00K---------

Ratios (Annual)

Figures in %.

Metric Jan 2010Jan 2011Dec 2011Dec 2012Dec 2013Jan 2015Jan 2016Dec 2016Dec 2017Dec 2018Dec 2019Jan 2021Jan 2022Dec 2022Dec 2023Dec 2024Jan 2026
Gross Margin % 49.8%50.1%49.1%48.3%48.6%50.0%47.8%45.1%37.3%41.0%41.3%42.8%42.4%44.5%42.0%40.1%36.5%
Operating Margin % 4.0%3.7%5.8%-2.5%6.9%6.0%0.7%-5.6%-31.0%-30.2%-20.7%-18.1%-14.0%-13.2%-19.3%-17.1%-4.9%
Net Margin % 8.3%9.4%7.9%4.2%5.8%23.4%1.1%-25.4%-30.9%-30.1%-20.3%-17.4%-9.7%-13.2%-18.5%-18.3%-8.4%
ROE % 17.2%15.7%11.6%6.6%8.6%29.8%1.4%-29.9%-42.2%-42.8%-38.8%-36.4%-22.4%-43.8%-100.5%-424.9%-90.1%
ROCE % -5.9%8.3%-3.8%10.0%7.4%0.8%-6.4%-41.2%-41.3%-35.8%-34.1%-20.9%-25.3%-46.6%-66.0%-16.1%

Shareholding Pattern

Insiders
36.82%
Institutions
19.46%
Public Float
30.80%

Top Institutional Holders

#Holder% HeldSharesValue
1 Paragon Associates & Paragon Associates Ii Joint Venture 5.69% 1.00M $670.00K
2 Vanguard Capital Management LLC 2.93% 514.59K $344.78K
3 Renaissance Technologies, LLC 2.41% 423.54K $283.77K
4 Morgan Stanley 1.74% 305.19K $204.48K
5 Weber Capital Management LLC /ADV 1.03% 180.45K $120.90K
6 Geode Capital Management, LLC 0.79% 138.96K $93.10K
7 Citadel Advisors Llc 0.56% 98.95K $66.30K
8 Perkins Capital Management, Inc. 0.40% 70.80K $47.44K
9 Vanguard Fiduciary Trust Co 0.34% 60.16K $40.30K
10 State Street Corporation 0.25% 44.72K $29.96K

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for IRIX

Yahoo Finance ue, 25 Aug 2026

IRIDEX (IRIX) Q2 2026 Earnings Call Transcript

Glaucoma probe sales surged 35% as retina revenue declined amid international transitions.

Yahoo Finance Wed, 19 Aug 2026

IRIDEX Corp (IRIX) (Q2 2026) Earnings Call Highlights: Cyclo-G6 Surges 35% as Company Achieves ...

Despite a 7% revenue dip from retina headwinds, IRIDEX Corp (IRIX) posts record glaucoma probe volume and reaffirms full-year guidance.

Yahoo Finance Mon, 20 Jul 2026

Iridex Adds EndoProbe® Handpieces to EyeProGPO Product Offering

MOUNTAIN VIEW, Calif., July 20, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma a…

Yahoo Finance Mon, 25 May 2026

IRIX Stock Up 4% As Q1 Loss Narrows Y/Y on Glaucoma Product Growth

IRIDEX posts a narrower year-over-year net loss per share in Q1'26 as strong glaucoma product sales and lower operating costs helped offset weakness in retina sales and supply-chain disruptions.

Yahoo Finance Wed, 20 May 2026

IRIDEX Corp (IRIX) Q1 2026 Earnings Call Highlights: Navigating Challenges with Strategic ...

IRIDEX Corp (IRIX) reports a milestone in profitability and strategic partnerships amid international headwinds and supply chain challenges.

Yahoo Finance ue, 05 May 2026

Iridex to Report First Quarter 2026 Financial Results on May 19, 2026

MOUNTAIN VIEW, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma an…

IRIX — Frequently Asked Questions

What is the current share price of IRIDEX Corporation (IRIX)?

As of 2026-09-19 21:16 PDT, IRIDEX Corporation (IRIX) trades at $0.68 on NasdaqCM. Its 52-week range is $0.68 to $1.56.

What is the market capitalisation of IRIX?

IRIDEX Corporation (IRIX) has a market capitalisation of $11.94M on NasdaqCM.

What is the P/E ratio of IRIX?

IRIX trades at a trailing price-to-earnings (P/E) ratio of -3.40. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is -4.96.

What is the return on equity (ROE) of IRIX?

IRIX has a return on equity (ROE) of -73.15%. Its return on capital employed (ROCE) is -16.13%.

Is IRIX a good stock to buy?

This page provides a data-driven analysis of IRIDEX Corporation (IRIX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space